Shanghai Miracogen Inc.

Quick facts

Phase 3 pipeline

• Cetuximab injection · Oncology
  Cetuximab is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing growth signals and inducing cell death.
• Gemcitabine, Docetaxel, or Capecitabine · Oncology
  This is a combination of three chemotherapy agents that work through different mechanisms to inhibit cancer cell growth and division.
• MRG002 · Oncology
  MRG002 is a bispecific antibody that simultaneously engages tumor-associated antigens and immune effector cells to enhance anti-tumor immunity.
• MRG003 · Oncology
  MRG003 is a bispecific antibody that simultaneously engages tumor cells and immune cells to enhance anti-tumor immunity.
• MRG003 + Pucotenlimab · Oncology
  MRG003 is a bispecific antibody targeting PD-L1 and 4-1BB that enhances T-cell activation, while Pucotenlimab is a PD-L1 inhibitor, together blocking immune checkpoints to reinvigorate anti-tumor immunity.
• MRG004A plus best supportive care · Oncology
  MRG004A is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses.
• Pemetrexed Disodium Injection · Oncology
  Pemetrexed is a folate antagonist that inhibits multiple enzymes involved in nucleotide synthesis, disrupting DNA and RNA production in cancer cells.
• Placebo plus best supportive care
  Placebo plus best supportive care provides no active pharmacological intervention, serving as a control arm to evaluate the efficacy of investigational treatments.
• Trastuzumab Emtansine for Injection · Oncology
  Trastuzumab emtansine targets the HER2 protein on cancer cells and delivers a toxic payload to kill them.

Phase 1 pipeline

• MRG001
• MRG004A

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Shanghai Miracogen Inc. portfolio CI brief
• Shanghai Miracogen Inc. pipeline updates RSS